Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Continuous vs. fixed duration therapy for multiple myeloma?

Jesús San Miguel • 5 Oct 2018
ESH MM 2018
Multiple Myeloma

Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jesús San Miguel, MD, PhD, of the University of Navarra, Pamplona, Spain, discusses continuous and fixed duration therapy.

More from Jesús San Miguel

Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023
1:11
The future of myeloma therapy and where the treatment landscape is moving
Jesús San Miguel • 13 May 2022
1:21
The value of sustained MRD negativity in MM
Jesús San Miguel • 13 May 2022
1:21
MRD evaluation: how, when and for which goal?
Jesús San Miguel • 13 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals